banter and General Discussion, page-17330

First 17330 Last

Share
Profile

Follow
ddwn

13,201 Posts.

3623

27/05/25

12:47

Post #: 79204037
Share

Originally posted by reginaldp: ↑

We used to defend the science and the personal risk we chose to take on when investing in a biotech.

The detractors were few but they were relentless and in the end were made to look foolish.

Now the detractors are plentiful , ignorant and cannot comprehend how the roll out is staged. They have zero interest re the upcoming CHF meeting and wait fearfully for proof that Ryoncil is selling, some question whether it is even working.

When they raise such stupidity I have become an expert at placing them on ignore. That is why I don't engage as much anymore, I'm not following the conversations the regulars are engaging in.

Ryoncil was approved, efficacy was never in doubt. It's rolling out, sales will shortly exceed ,annualised, US $100 million then we get Europe, off label and adult trial still to come. Tick tick boom.

Personally I think those questioning Ryoncil's rollout are imbeciles. It was an unmet need and we have the market to ourselves for 7 years! I'm now here for CHF- with the regime change and pro new therapy team to Make America Health Again I think we are extremely well placed for a possible Accelerated Approval- which will partner us with a Global giant. Global being the key word here. 80% reduction in heart attacks for heart failure patients with elevated CRP being sold across the world. My mind boggles at the opportunity as reference pricing for Ryoncil tripled expectations.

Ryoncil is derisked, Revascor in now in play. I'm excited.

You do you........................................... those on ignore deserve each other

Reg

Expand

Agree & nice one Reg, keep up the spirit!

I hate the SP bleeding, but with Ryoncil approved - it will be a matter of time for the sales $$$ to kick in.

We’ll have our days, weeks, months and years in the sun - eventually

GL MSB’ers onwards & upwards

MSB Price at posting: $1.63 Sentiment: Buy Disclosure: Held
32 Upvote

0 Great analysis

Reply

Top Stories

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

First 17330 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.66		Change 0.038(2.31%)		Mkt cap ! $2.114B

Open	High	Low	Value	Volume
$1.64	$1.67	$1.63	$2.273M	1.379M

Buyers (Bids)

No.	Vol.	Price($)
2	768	$1.66

Sellers (Offers)

Price($)	Vol.	No.
$1.66	44100	22

View Market Depth

No.	Vol.	Price($)
25	38361	1.650
10	65015	1.645
22	108579	1.640
13	127590	1.635
14	84626	1.630

Price($)	Vol.	No.
1.655	7520	6
1.660	48343	26
1.665	73265	15
1.670	130395	16
1.675	122290	11

Last trade - 13.13pm 27/06/2025 (20 minute delay)

MSB (ASX) Chart

banter and General Discussion, page-17330

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

banter and General Discussion, page-17330

Top Stories

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News